Latest news with #HSIC
Yahoo
5 days ago
- Business
- Yahoo
Is Henry Schein Stock Outperforming the Dow?
Melville, New York-based Henry Schein, Inc. (HSIC) provides healthcare products and services to office-based dental and medical practitioners, and alternate sites of care worldwide. With a market cap of $8.9 billion, the company operates through Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology segments. Companies valued between $2 billion and $10 billion are generally classified as 'mid-cap stocks," and Henry Schein fits this criterion perfectly. The company offers a wide range of solutions, including medical and dental supplies, equipment, and cutting-edge technology products, such as practice management software and revenue cycle solutions, enhancing efficiency and delivering quality patient care. Tesla's Robotaxis Reportedly Sped and Veered Into the Wrong Lanes. Does This Crush the Bull Case for TSLA Stock? Is United Health Stock a Buy, Hold or Sell for July 2025? Dear Micron Stock Fans, Mark Your Calendars for June 25 Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Henry Schein currently trades 11.8% below its 52-week high of $82.49 recorded on Feb. 5. HSIC's stock has gained 4.9% over the past three months, outpacing the broader Dow Jones Industrial Average's ($DOWI) marginal rise. Longer term, Henry Schein's stock has surged 5.2% on a YTD basis, whereas the Dow has increased 1%. Moreover, shares of HSIC soared 10.1% over the past 52 weeks, slightly outperforming the Dow Jones' 9.9% returns over the same time frame. The stock has risen above its 50-day moving average since early May and traded along its flat 200-day moving average in recent weeks. Henry Schein's stock rose 2% following the release of its mixed Q1 2025 results on May 5. The company reported net sales of $3.2 billion, a marginal decline from the year-ago quarter, missing the consensus estimate. However, its net sales rose 1.4% on a constant currency basis. The Global Technology segment recorded 3.2% growth, driven by demand for practice management systems and revenue cycle management products. Meanwhile, its adjusted EPS grew 4.5% from the prior-year quarter to $1.15, surpassing analysts' estimate by 3.6%. Looking ahead, the company reaffirmed its full-year adjusted EPS guidance of $4.80 to $4.94, reflecting 1% to 4% growth from the reported figure of 2024, and maintained its revenue growth outlook of 2% to 4% for 2025. Compared to its peer, Cardinal Health, Inc. (CAH) has notably outperformed HSIC stock. Shares of CAH have gained 38.5% on a YTD basis and climbed 58.8% over the past 52 weeks. Among the 14 analysts covering the HSIC stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $76.54 suggests a 5.2% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
25-06-2025
- Business
- Yahoo
Leerink Partners Keeps a Hold Rating on Henry Schein (HSIC) With a $69 PT
Henry Schein, Inc. (NASDAQ:HSIC) is one of the . On June 16, Leerink Partners analyst Michael Cherny maintained a Hold rating on Henry Schein, Inc. (NASDAQ:HSIC) and set a price target of $69.00. The company also announced the successful completion of a $250 million strategic investment on May 16, which was extended by funds affiliated with KKR, a leading global investment firm. The closing of the transaction made KKR the holder of around 12% of the company's common shares. A close-up of a patient's mouth, the dental products from the company in view. Henry Schein, Inc. (NASDAQ:HSIC) reported a 22% growth in GAAP diluted EPS for fiscal Q1 2025, reaching $0.88. Non-GAAP diluted EPS for the quarter underwent a 4.5% rise to $1.15 when compared to the same period last year. Henry Schein, Inc. (NASDAQ:HSIC) is also advancing its BOLD+1 Strategic Plan, refreshing it for the 2025 to 2027 period. The plan focuses on expanding the company's corporate brand products and dental and medical specialty businesses, growing its distribution business by improving customer experience and rising operational efficiency, and developing its digital solutions and digital footprint. Henry Schein, Inc. (NASDAQ:HSIC) provides healthcare services and products to medical, veterinary, and dental office-based practitioners. It operates in the Healthcare Distribution and Technology and Value-Added Services business segments. While we acknowledge the potential of HSIC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
07-05-2025
- Business
- Yahoo
Henry Schein First Quarter 2025 Earnings: Misses Expectations
Henry Schein (NASDAQ:HSIC) First Quarter 2025 Results Key Financial Results Revenue: US$3.17b (flat on 1Q 2024). Net income: US$110.0m (up 18% from 1Q 2024). Profit margin: 3.5% (up from 2.9% in 1Q 2024). EPS: US$0.89 (up from US$0.72 in 1Q 2024). Our free stock report includes 2 warning signs investors should be aware of before investing in Henry Schein. Read for free now. NasdaqGS:HSIC Earnings and Revenue Growth May 7th 2025 All figures shown in the chart above are for the trailing 12 month (TTM) period Henry Schein Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) also missed analyst estimates by 2.7%. Looking ahead, revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's share price is broadly unchanged from a week ago. Risk Analysis You still need to take note of risks, for example - Henry Schein has 2 warning signs we think you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
San Francisco Chronicle
05-05-2025
- Business
- San Francisco Chronicle
Henry Schein: Q1 Earnings Snapshot
MELVILLE, N.Y. (AP) — MELVILLE, N.Y. (AP) — Henry Schein Inc. (HSIC) on Monday reported first-quarter profit of $110 million. On a per-share basis, the Melville, New York-based company said it had net income of 88 cents. Earnings, adjusted for one-time gains and costs, were $1.15 per share. The results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of $1.11 per share. The health care products maker posted revenue of $3.17 billion in the period, missing Street forecasts. Nine analysts surveyed by Zacks expected $3.23 billion.
Yahoo
25-03-2025
- Business
- Yahoo
Is Henry Schein, Inc.'s (NASDAQ:HSIC) Stock Price Struggling As A Result Of Its Mixed Financials?
With its stock down 8.4% over the past month, it is easy to disregard Henry Schein (NASDAQ:HSIC). It seems that the market might have completely ignored the positive aspects of the company's fundamentals and decided to weigh-in more on the negative aspects. Fundamentals usually dictate market outcomes so it makes sense to study the company's financials. Specifically, we decided to study Henry Schein's ROE in this article. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. The formula for return on equity is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Henry Schein is: 8.2% = US$398m ÷ US$4.8b (Based on the trailing twelve months to December 2024). The 'return' is the yearly profit. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.08. View our latest analysis for Henry Schein We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes. When you first look at it, Henry Schein's ROE doesn't look that attractive. We then compared the company's ROE to the broader industry and were disappointed to see that the ROE is lower than the industry average of 11%. Therefore, it might not be wrong to say that the five year net income decline of 11% seen by Henry Schein was probably the result of it having a lower ROE. We believe that there also might be other aspects that are negatively influencing the company's earnings prospects. Such as - low earnings retention or poor allocation of capital. So, as a next step, we compared Henry Schein's performance against the industry and were disappointed to discover that while the company has been shrinking its earnings, the industry has been growing its earnings at a rate of 4.1% over the last few years. Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. What is HSIC worth today? The intrinsic value infographic in our free research report helps visualize whether HSIC is currently mispriced by the market. Because Henry Schein doesn't pay any regular dividends, we infer that it is retaining all of its profits, which is rather perplexing when you consider the fact that there is no earnings growth to show for it. So there could be some other explanations in that regard. For instance, the company's business may be deteriorating. Overall, we have mixed feelings about Henry Schein. While the company does have a high rate of profit retention, its low rate of return is probably hampering its earnings growth. Having said that, looking at current analyst estimates, we found that the company's earnings growth rate is expected to see a huge improvement. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
